Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 19/20 | 0.83 |
| ▸ | KDR | P35968 | 19/20 | 0.83 |
| ▸ | FGFR1 | P11362 | 17/20 | 0.83 |
| ▸ | FLT4 | P35916 | 15/20 | 0.83 |
| ▸ | EGFR | P00533 | 14/20 | 0.83 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.69 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2140901 | 0.91 | FLT1 (0.98) | FLT1KDRFGFR1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL27218181 | 0.91 | FLT1 (1.00) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL5424040 | 0.91 | KDR (1.00) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL14095983 | 0.89 | FGFR1 (1.00) | FLT1KDRFGFR1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL4086431 | 0.85 | FLT1 (0.78) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL1468157 | 0.84 | KDR (0.74) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL3202554 | 0.84 | KDR (0.69) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL2203010 | 0.84 | FLT1 (0.73) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL1468310 | 0.84 | FLT1 (0.85) | FLT1KDRFGFR1FLT4EGFR | |
| SCHEMBL7867151 | 0.84 | FLT1 (1.00) | FLT1KDRFGFR1FLT4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | ASTRAZENCA (SE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | ASTRAZENCA (SE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | ASTRAZENCA (SE) | 2007-02-01 | — | — | US | disclosed |
| EP-1653965-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | Astrazeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005013998-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | FLT4, FLT1, VEGFA | FLT1 2/4885KDR 4/4885FGFR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.